Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Philipp Csomor"'
Autor:
Michael J. Germain, Subir K. Paul, George Fadda, Varshasb Broumand, Andy Nguyen, November H. McGarvey, Matthew D. Gitlin, Charles W. Bishop, Philipp Csomor, Stephen Strugnell, Akhtar Ashfaq
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Introduction Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic kid
Externí odkaz:
https://doaj.org/article/ea5d7f0a4e0d41f78b22eb2bdd5d89d2
Publikováno v:
Kidney Diseases (2023)
Abstract Introduction: Parathyroid hormone-lowering responses after administration of three different therapies capable of raising serum total 25-hydroxyvitamin D (25OHD) were evaluated in patients with secondary hyperparathyroidism (SHPT), vitamin D
Externí odkaz:
https://doaj.org/article/412507117a024bf58c41f4c84ec28e79
Publikováno v:
American Journal of Nephrology. 53:446-454
Introduction: Obesity increases the risk of vitamin D insufficiency, which exacerbates secondary hyperparathyroidism in chronic kidney disease. Recent studies suggest that serum total 25-hydroxyvitamin D (25OHD) levels of ≥50 ng/mL are necessary to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b005662fb31dd72a6cea8cfa4dad1e3
https://doi.org/10.1159/000524289
https://doi.org/10.1159/000524289
Autor:
Jordi Bover, Giuseppe Cianciolo, Philipp Csomor, Joel Gunnarsson, Edelgard Kaiser, Rosa Lauppe
Publikováno v:
Clinical Kidney Journal
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Secondary hyperparathyroidism (SHPT) is a common and major complication in chronic kidney disease (CKD), reflecting the increase of parathyroid hormone (PTH) in response to reduced vitamin D signalling and hypocalcaemia. This meta-analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c976985c6ca5e340e039ad47e85d1ba0
https://pubmed.ncbi.nlm.nih.gov/34603696
https://pubmed.ncbi.nlm.nih.gov/34603696
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Chronic kidney disease (CKD) is commonly associated with mineral and bone disorder (CKD-MBD). Secondary hyperparathyroidism (SHPT) is a critical component of CKD-MBD characterized by excessive PTH secretion and parathyroid hyperpl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f66ccfbb57431a4a6e96af903b5bc9e7
https://doi.org/10.1093/ndt/gfaa142.p0891
https://doi.org/10.1093/ndt/gfaa142.p0891
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:8-8
IntroductionSecondary hyperparathyroidism (SHPT) is a consequence of non-dialysis chronic kidney disease (ND-CKD), causing disturbances in metabolic parameters including increased phosphate and parathyroid hormone (PTH) and reduced calcium serum leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::353db1ae9c3ac2f456019924c9bb90ab
https://doi.org/10.1017/s0266462320001075
https://doi.org/10.1017/s0266462320001075